Mode
Text Size
Log in / Sign up
Phase 3 N=22 Single-blind Treatment

Weight Regain Treatment Post-Bariatric Surgery

Obesity, Overweight

Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Nov 2023
Primary outcome: Primary: Body Mass Index — 39.12; 40.48 kg/m2

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Behavioral Weight Loss (BWL) (Behavioral); Early Responder: BWL continued (Behavioral); Early Non-responder: BWL continued with medication added (Combination_product)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Yale University
Primary completion
Sep 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Body Mass Index
39.12; 40.48
SECONDARY
Eating Disorder Psychopathology
1.53; 1.46
SECONDARY
Food Craving
1.65; 1.57
SECONDARY
Depressive Symptoms
3.89; 3.67

Summary

This study will examine behavioral and pharmacologic (Naltrexone+Bupropion) treatments for weight regain after bariatric surgery.

Eligibility Criteria

Inclusion Criteria

  • Be in the age range ≥18 years of age and ≤70 years of age
  • Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and ≤50 kg/m2
  • Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy
  • Experiencing weight regain after bariatric surgery
  • Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies).
  • Read, comprehend, and write English at a sufficient level to complete study-related materials.
  • Provide a signed and dated written informed consent prior to study participation.
  • Be available for participation in the study for up to 3 months.

Exclusion Criteria

  • Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).
  • Has a history of anorexia nervosa or history of bulimia nervosa.
  • Is currently taking a medication that is a contraindication to NB medication (e.g., MAOI, opiates).
  • Is currently using other medications for weight loss.
  • Has a history of allergy or sensitivity to bupropion or naltrexone.
  • Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
  • Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute.
  • Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.
  • Has current uncontrolled hypertension.
  • Has current uncontrolled Type I or Type II diabetes mellitus.
  • Has untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit.
  • Has gallbladder disease.
  • Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder.
  • Has a recent history of drug or alcohol dependence (since having bariatric surgery).
  • Is currently in active treatment for eating or weight loss.
  • Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
  • Is breast-feeding or is pregnant or is not using a reliable form of birth control.
  • Reports active suicidal or homicidal ideation.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04662801). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search